AlloVir, Inc.

Equities

ALVR

US0198181036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7971 ^USD	-0.36%		+6.25%	+17.26%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 15	AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 15, 2024 at 08:43 am EDT

AlloVir, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 190.42 million compared to USD 168.71 million a year ago. Basic loss per share from continuing operations was USD 1.83 compared to USD 2.2 a year ago.

Latest news about AlloVir, Inc.

North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	Dec. 27	DJ
Sector Update: Health Care	Dec. 22	MT
Morgan Stanley Downgrades AlloVir to Equalweight From Overweight, Cuts Price Target to $1 From $20	Dec. 22	MT
AlloVir Shares Plummet as Global Trials of Anti-Viral T-Cell Therapy to be Discontinued	Dec. 22	MT
Top Midday Decliners	Dec. 22	MT
Sector Update: Health Care Stocks Gain in Late Afternoon	Dec. 22	MT
AlloVir scraps late-stage studies testing lead cell therapy	Dec. 22	RE
AlloVir scraps late-stage studies testing antiviral cell therapy	Dec. 22	RE
AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy	Dec. 22	CI
Leerink Partners Downgrades AlloVir to Market Perform From Outperform, Cuts Price Target to $1 From $14	Dec. 22	MT
Piper Sandler Downgrades AlloVir to Neutral From Overweight, Cuts Price Target to $1.50 From $27	Dec. 22	MT
JPMorgan Downgrades AlloVir to Underweight From Overweight	Dec. 22	MT
AlloVir to Review Strategic Alternatives for the Company and Its Portfolio of Virus-Specific T Cell Therapies	Dec. 22	CI
AlloVir, Inc.(NasdaqGS:ALVR) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
AlloVir, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Certain Restricted Stock Units of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	23-09-19	CI
Certain Stock Options of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	23-09-19	CI
Certain Common Stock of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	23-09-19	CI
Transcript : AlloVir, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 04:55 PM	23-09-11
Sector Update: Health Care Stocks Declining Late Afternoon	23-08-18	MT
Sector Update: Health Care Stocks Easing Friday Afternoon	23-08-18	MT

Chart AlloVir, Inc.

Duration

Period

More charts

Company Profile

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.7971 USD

Average target price

1 USD

Spread / Average Target

+25.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLOVIR, INC.	+17.26%	89M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs